Efficacies of Single-Dose Ceftriaxone Regimens in Treating Gonococcal Paraurethral Duct Infection in Men

This study compared the efficacies of single-dose ceftriaxone therapy at doses of 250 mg, 500 mg, and 1 g for gonococcal paraurethral duct infection in men. Forty-eight men with gonococcal paraurethral duct infection were assigned to Groups A, B, and C based on their order of arrival in the clinic; each group comprised 16 patients. Groups A, B, and C received single intramuscular doses of ceftriaxone at 250 mg, 500 mg, and 1 g, respectively. The mean times to resolution of purulent discharge from the paraurethral duct were 1.87 ± 0.81 days in Group A, 1.06 ± 0.25 days in Group B, and 1.13 ± 0.34 days in Group C. The mean times to resolution of erythematous swelling at skin lesions were 4.75 ± 1.69 days in Group A, 3.44 ± 0.89 days in Group B, and 3.31 ± 1.25 days in Group C. The mean times to resolution of tenderness at skin lesions were 5.25 ± 1.00 days in Group A, 3.06 ± 0.10 days in Group B, and 2.38 ± 1.03 days in Group C. The mean times to closure of the paraurethral duct orifice were 9.88 ± 2.92 days in Group A, 6.88 ± 1.71 days in Group B, and 6.38 ± 1.86 days in Group C. The resolution times significantly differed between Group A and Groups B and C (all p < .05); however, there were no significant differences between Groups B and C (all p > .05). The study shows that all three ceftriaxone single-dose regimens effectively cured gonococcal paraurethral duct infection in men. A single 500 mg dose may represent a more suitable treatment option.